Survival Outcomes of Lung Cancer
This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.
Lung Cancer
DRUG: Treatment
Progression-free survival (PFS), PFS defines as first dose to first documented disease progression assessed by investigator or death due to any cause., Time from first subject dose to study completion, or up to 5 years
Overall survival (OS), To assess overall response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as the proportion of subjects who have a complete response (CR) or a partial response (PR), Time from first subject dose to study completion, or up to 5 years|Adverse events (AEs), Number of participants with adverse events (AEs) according to CTCAE 5.0, Time from first subject dose to study completion, or up to 5 years
This study aims to analyze the survival outcomes of different groups about lung cancer patients. All the groups were assessed to the treatment decisions guided by molecular profiling and clinical judgment of principal investigators